Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring.

  title={Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring.},
  author={Kaneo Satoh and Isao Fukasawa and Kazuya Kanemaru and Shigemi Yoda and Yukio Kimura and Osamu Inoue and Masato Ohta and Hiroyuki Kinouchi and Yukio Ozaki},
  journal={Thrombosis research},
  volume={130 4},

Figures and Tables from this paper

Assessment of Cilostazol Inhibition Using Whole Blood Samples : Comparison of Three Platelet Function Tests
The IIb/IIIa tests of VerifyNow in the presence of 10 nM PGE1 is the most suitable tool for monitoring assessing cilostazol.
Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot
Given with aspirin, clopidogrel, or cilostazol in rats, BPC 157 counteracted their inhibitory effects on aggregation activated by arachidonic acid, ADP, collagen, and arachidsonic acid/PGE1.
Clinical Utility of Platelet Function Testing Following Non-Cardioembolic Stroke.
It is indicated that selection of the optimum antiplatelet agent based on the platelet functional assays for each individual patient may contribute to a reduction in the incidence of recurrence of ischemic stroke.
Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease
Aspirin showed better antiplatelet effects assessed with VerifyNow and PFA-100 compared with cilostazol, however, there were favorable changes in atherogenic dyslipidemia only in the cilstazol.
Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood–brain barrier
  • T. Takagi, Takahiko Imai, H. Hara
  • Medicine, Biology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2017
Cilostazol reduced collagenase-induced intracranial hemorrhage volume by protecting the blood–brain barrier.
Exposure to Blood Components and Inflammation Contribute to Pancreatic Cancer Progression
Blood components, especially platelets, and inflammation enhance the malignant behaviors of pancreatic cancer cells, potentially contributing to poor prognosis for pancreatectomy patients.
What methods are being used to create an evidence base on the use of laboratory tests to monitor long-term conditions in primary care? A scoping review
The extent and nature of research that provides evidence on the use of laboratory tests to monitor long-term conditions in primary care is mapped, and gaps in existing research are found to address.


Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.
The antiplatelet effects of cilostazol intake could be evaluated by measuring VASP phosphorylation levels and maximal aggregation rates in platelets by ex vivo treatment with a low concentration of PGE(1).
Effect of cilostazol on platelet aggregation and experimental thrombosis.
The drug potently prevented death due to pulmonary thrombosis by platelet aggregates in mice in vivo and cilostazol is a promising antithrombotic drug.
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol
A platelet VASP assay can detect the platelet response to cilostazol with high sensitivity and specificity and is demonstrated to be reliable for clinical use.
Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
A new antithrombotic drug, cilostazol, was orally administered at 50, 100, 150 and 200 mg daily for four weeks to 24 patients with cerebrovascular diseases including cerebral thrombosis, cerebral embolism, transient ischemic attacks and cerebral arteriosclerosis suggesting the therapeutic value of the drug even by single administration.
Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease.
The new antithrombotic drug cilostazol was administered at daily oral doses of 75, 150 and 300 mg for 2 weeks in 15 patients with cerebrovascular disease and can be considered to be a potent and safe antiplatelet-aggregating agent.
Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.
Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary
Adjustment of PRP for platelet count does not provide any advantage and therefore the time‐consuming process of Platelet count adjustment is not necessary, whereas late aggregation using ADP 2 μm in non‐adjusted PRP offers the best discrimination between clopidogrel‐treated patients and healthy controls.
Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study.
A randomized double-blind cross-over study to determine the inhibitory effects of acetylsalicylic acid, ticlopidine and cilostazol and CS, a new antithrombotic agent on platelet functions ex vivo found that CS and TP significantly inhibited platelet aggregation induced by ADP.
Cilostazol, an Inhibitor of Type 3 Phosphodiesterase, Produces Endothelium-Independent Vasodilation in Pressurized Rabbit Cerebral Penetrating Arterioles
The vasodilator action of cilostazol may, in part, contribute to the beneficial effect of preventing lacunar cerebral infarction in patients with functional damage of the endothelium in cerebral penetrating arterioles.
Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.
  • F. Gotoh, H. Tohgi, Y. Ohashi
  • Medicine
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • 2000
Long-term administration of cilostazol was effective and safe in the secondary prevention of cerebral infarction and a significant relative-risk reduction was shown in the recurrence of cerebralinfarction.